<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article article-type="other">
  <?properties open_access?>
  <!-- Original-type: cl-->
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id>
      <journal-title>British Journal of Cancer</journal-title>
      <issn pub-type="ppub">0007-0920</issn>
      <issn pub-type="epub">1532-1827</issn>
      <publisher>
        <publisher-name>Nature Publishing Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">12698177</article-id>
      <article-id pub-id-type="pmc">2747559</article-id>
      <article-id pub-id-type="pii">6600893</article-id>
      <article-id pub-id-type="doi">10.1038/sj.bjc.6600893</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Clinical</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Dose-dependent severe cutaneous reactions to imatinib</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Ugurel</surname>
            <given-names>S</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff3">3</xref>
          <xref ref-type="corresp" rid="caf1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hildenbrand</surname>
            <given-names>R</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dippel</surname>
            <given-names>E</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schadendorf</surname>
            <given-names>D</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label><sup>1</sup>Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany</aff>
      <aff id="aff2"><label>2</label><sup>2</sup>Institute of Pathology, University Hospital of Mannheim, 68167 Mannheim, Germany</aff>
      <aff id="aff3"><label>3</label><sup>3</sup>Department of Dermatology, University Hospital of Mannheim, 68167 Mannheim, Germany</aff>
      <aff id="aff4"><label>4</label><sup>4</sup>Department of Internal Medicine, University Hospital of Mannheim, 68167 Mannheim, Germany</aff>
      <author-notes>
        <corresp id="caf1"><label>*</label>Author for correspondence: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:s.ugurel@dkfz.de">s.ugurel@dkfz.de</email></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>15</day>
        <month>04</month>
        <year>2003</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <day>22</day>
        <month>04</month>
        <year>2003</year>
      </pub-date>
      <volume>88</volume>
      <issue>8</issue>
      <fpage>1157</fpage>
      <lpage>1159</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>01</month>
          <year>2003</year>
        </date>
        <date date-type="accepted">
          <day>03</day>
          <month>02</month>
          <year>2003</year>
        </date>
      </history>
      <copyright-statement>Copyright 2003, Cancer Research UK</copyright-statement>
      <copyright-year>2003</copyright-year>
      <permissions>
        <copyright-holder>Cancer Research UK</copyright-holder>
      </permissions>
      <abstract>
        <p>The protein kinase inhibitor imatinib has been approved as an efficient anticancer drug with common but mild cutaneous toxicities. We here report on two out of four melanoma patients treated with high-dose imatinib presenting with severe and strongly dose-dependent skin eruptions, suggesting a cutaneous reactivity pattern different from allergic hypersensitivity. </p>
      </abstract>
      <kwd-group>
        <kwd>imatinib</kwd>
        <kwd>melanoma</kwd>
        <kwd>adverse drug reaction</kwd>
        <kwd>c-kit</kwd>
        <kwd>mast cells</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Imatinib mesylate (Gleevec, formerly STI571, Novartis, Basel, Switzerland) is a selective inhibitor of the tyrosine kinase family including the oncogenes Abl and Kit as well as the platelet-derived growth factor receptor (PDGF-R). Owing to its mechanisms of action, imatinib has been used successfully in chronic myelogenous leukaemia (CML) and in gastrointestinal stromal tumours (GIST). Dose-escalation studies proved imatinib as a well-tolerated oral drug with rare dose-limiting toxicities (<xref ref-type="other" rid="bib3">Druker <italic>et al</italic>, 2001</xref>). Nevertheless, severe cutaneous side effects have been reported, leading to a cessation of imatinib treatment in single cases (<xref ref-type="other" rid="bib1">Brouard and Saurat, 2001</xref>).</p>
    <p>We here report on the first four patients being enrolled into a clinical phase II study investigating imatinib as a second-line therapy in advanced melanoma. The study's rationale was based on the well-known expression of c-kit as well as PDGF-R in melanoma cell lines and tissues (<xref ref-type="other" rid="bib6">Ohashi <italic>et al</italic>, 1996</xref>). Albeit the patients' clinical outcome still has to be awaited, we hereby provide a first report of the noticeable strong and frequent cutaneous adverse events.</p>
    <sec>
      <title>DESCRIPTION OF CASES</title>
      <p>All four patients received imatinib 400&#x2009;mg b.i.d. (800&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>) after progression of melanoma disease under a first-line cytostatic regimen was ascertained. Patients' clinical data are summarized in <xref rid="tbl1" ref-type="table">Table 1(A)</xref>
 <table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p content-type="table-title">Skin reactions to imatinib</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>(A)</bold></th><th align="left" valign="top" charoff="50"><bold>Age (years)/gender</bold></th><th align="left" valign="top" charoff="50"><bold>Localization of metastases</bold></th><th align="left" valign="top" charoff="50"><bold>Skin reaction</bold></th><th align="left" valign="top" charoff="50"><bold>CTC grading</bold></th><th align="left" valign="top" charoff="50"><bold>Onset of reaction (days after first application of imatinib)</bold></th><th align="left" valign="top" charoff="50"><bold>Dose adjustment</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Patient 1</td><td align="left" valign="top" charoff="50">71/m</td><td align="left" valign="top" charoff="50">Liver, spleen, subcutaneous</td><td align="left" valign="top" charoff="50">None</td><td align="left" valign="top" charoff="50">0</td><td align="left" valign="top" charoff="50">None</td><td align="left" valign="top" charoff="50">None</td></tr><tr><td align="left" valign="top" charoff="50">Patient 2</td><td align="left" valign="top" charoff="50">51/f</td><td align="left" valign="top" charoff="50">Lung, subcutaneous</td><td align="left" valign="top" charoff="50">Generalised macular and urticarial eruption</td><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">10</td><td align="left" valign="top" charoff="50">50% reduction</td></tr><tr><td align="left" valign="top" charoff="50">Patient 3</td><td align="left" valign="top" charoff="50">41/f</td><td align="left" valign="top" charoff="50">Lymph nodes, subcutaneous</td><td align="left" valign="top" charoff="50">Generalized macular and urticarial eruption</td><td align="left" valign="top" charoff="50">3</td><td align="left" valign="top" charoff="50">5</td><td align="left" valign="top" charoff="50">50% reduction, corticosteroids</td></tr><tr><td align="left" valign="top" charoff="50">Patient 4<hr/></td><td align="left" valign="top" charoff="50">69/f<hr/></td><td align="left" valign="top" charoff="50">Skin<hr/></td><td align="left" valign="top" charoff="50">Macular rash of the face<hr/></td><td align="left" valign="top" charoff="50">2<hr/></td><td align="left" valign="top" charoff="50">7<hr/></td><td align="left" valign="top" charoff="50">None<hr/></td></tr><tr><td align="left" valign="top" charoff="50"><bold>(B)</bold><hr/></td><td align="left" valign="top" charoff="50"><bold>Author, year of publication</bold><hr/></td><td align="left" valign="top" charoff="50"><bold>Imatinib dose (mg&#x2009;day<sup>&#x2212;1</sup>)</bold><hr/></td><td align="left" valign="top" charoff="50"><bold>Number of patients treated</bold><hr/></td><td align="left" valign="top" charoff="50">&#xA0;<hr/></td><td align="left" valign="top" charoff="50"><bold>Mild or moderate cutaneous reactions (CTC grade 1&#x2013;2)</bold><hr/></td><td align="left" valign="top" charoff="50"><bold>Severe cutaneous reactions (CTC grade 3&#x2013;4)</bold><hr/></td></tr><tr><td align="left" valign="top" charoff="50">CML</td><td align="left" valign="top" charoff="50">Kantarjian <italic>et al</italic> (2002)</td><td align="left" valign="top" charoff="50">400</td><td align="left" valign="top" charoff="50">532</td><td align="left" valign="top" charoff="50">&#xA0;</td><td align="left" valign="top" charoff="50">155 (29.1%)</td><td align="left" valign="top" charoff="50">16 (3.0%)</td></tr><tr><td align="left" valign="top" charoff="50">CML</td><td align="left" valign="top" charoff="50">Talpaz <italic>et al</italic> (2002)</td><td align="left" valign="top" charoff="50">400&#x2013;600</td><td align="left" valign="top" charoff="50">235</td><td align="left" valign="top" charoff="50">&#xA0;</td><td align="left" valign="top" charoff="50">49 (20.8%)</td><td align="left" valign="top" charoff="50">3 (1.3%)</td></tr><tr><td align="left" valign="top" charoff="50">CML</td><td align="left" valign="top" charoff="50">Sawyers <italic>et al</italic> (2002)</td><td align="left" valign="top" charoff="50">400&#x2013;600</td><td align="left" valign="top" charoff="50">260</td><td align="left" valign="top" charoff="50">&#xA0;</td><td align="left" valign="top" charoff="50">48 (18.5%)</td><td align="left" valign="top" charoff="50">11 (4.2%)</td></tr><tr><td align="left" valign="top" charoff="50">GIST</td><td align="left" valign="top" charoff="50">van Oosterom <italic>et al</italic> (2001)</td><td align="left" valign="top" charoff="50">400&#x2013;1000</td><td align="left" valign="top" charoff="50">40</td><td align="left" valign="top" charoff="50">&#xA0;</td><td align="left" valign="top" charoff="50">17 (42.5%)</td><td align="left" valign="top" charoff="50">5 (12.5%)</td></tr><tr><td align="left" valign="top" charoff="50">GIST</td><td align="left" valign="top" charoff="50">Demetri <italic>et al</italic> (2002)</td><td align="left" valign="top" charoff="50">400&#x2013;600</td><td align="left" valign="top" charoff="50">147</td><td align="left" valign="top" charoff="50">&#xA0;</td><td align="left" valign="top" charoff="50">41 (27.9%)</td><td align="left" valign="top" charoff="50">4 (2.7%)</td></tr></tbody></table><table-wrap-foot><fn id="tbfnote1"><label/><p>(A) Melanoma patients treated with imatinib 800&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>. (B) CML and GIST patients treated with different doses of imatinib. CTC=common toxicity criteria of the National Cancer Institute, National Institutes of Health; CML=chronic myelogenous leukaemia; GIST=gastrointestinal stromal tumour.</p></fn></table-wrap-foot></table-wrap>. Three of four patients showed moderate to strong cutaneous reactions with a macular and/or urticarial pattern within the first two weeks of therapy (<xref ref-type="fig" rid="fig1">Figure 1A, B</xref><fig id="fig1"><label>Figure 1</label><caption><p>Photographs and photomicrographs of patient 3 at day 10 after the onset of treatment with imatinib 800&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>. (<bold>A</bold>, <bold>B</bold>) Face and trunk of the patient showing generalised macular and urticarial cutaneous eruptions. (<bold>C</bold>) Haematoxylin&#x2013;eosin staining of lesional skin revealing a mononuclear infiltrate and marked oedema of the upper dermis; magnification 1&#x2009;:&#x2009;200. (<bold>D</bold>, <bold>E</bold>) Immunohistochemical staining of lesional skin showing strong expression of c-kit (CD117) in discrete mononuclear cells (arrows) of the upper dermis; magnification 1&#x2009;:&#x2009;100 (D) and 1&#x2009;:&#x2009;400 (<bold>E</bold>). (<bold>F</bold>) Giemsa staining revealing an increased number of mast cells (arrows) in the upper dermis of lesional skin; magnification 1&#x2009;:&#x2009;400.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="jpeg" xlink:href="88-6600893f1"/></fig>). The exanthema emanated from the face and trunk, and subsequently afflicted the extremities. Other side effects were of mild to moderate intensity including fluid retention, nausea, vomiting and fatigue. As a result of the severity of skin reactions, 50% dose adjustments became necessary in two of three patients. Additionally, corticosteroids (methylprednisolon 60&#x2009;mg&#x2009;day<sup>&#x2212;1</sup> p.o.) were given in one patient. The cutaneous eruptions regressed in all three patients within 2&#x2013;3 weeks. Thereafter, imatinib was again escalated to 75% of the initial dose (600&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>) in patients 2 and 3, leading to a strong relapse of skin eruptions in both cases. During the further course of treatment, imatinib was left at 50% reduction (400&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>) in these two patients, resulting in no further skin reactions.</p>
    </sec>
    <sec>
      <title>HISTOLOGICAL ANALYSES AND DISCUSSION</title>
      <p>A review of the literature revealed mild to moderate cutaneous reactions as a common side effect to imatinib (<xref rid="tbl1" ref-type="table">Table 1(B)</xref>). In contrast, severe skin reactions are rarely reported but, however, occurred following high treatment doses of 600&#x2013;1000&#x2009;mg&#x2009;day<sup>&#x2212;1</sup> as used in a phase I trial in GIST (<xref ref-type="other" rid="bib9">van Oosterom <italic>et al</italic>, 2001</xref>) as well as in our ongoing study. Histological analyses of biopsy specimens of lesional skin from patients 2 and 3 revealed loose mononuclear cells infiltrating the dermis with a perivascular pattern (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). The upper dermis showed marked oedema and, remarkably, an increased number of mast cells. Immunohistochemical analyses using polyclonal goat-anti-human antibodies A4502 (DAKO, Hamburg, Germany) recognising the c-kit gene product CD117 revealed a strong staining of mononuclear cells of the dermis morphologically corresponding to mast cells (<xref ref-type="fig" rid="fig1">Figure 1D, E</xref>), as additionally confirmed by Giemsa staining (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Human mast cells, which express a functional c-kit receptor, are known to be susceptible to tyrosine kinase inhibition by imatinib leading to impaired proliferation as well as induction of apoptosis (<xref ref-type="other" rid="bib5">Ma <italic>et al</italic>, 2002</xref>). Therefore, an enhanced proliferation of mast cells as observed in our patients seems to be unlikely mediated via c-kit inhibition on the mast cells themselves. We therefore suggest imatinib to act as a dose-dependent inducer of chemoattractant substances like, for example, cytokines and growth factors leading to dermal mast cell accumulation. Nevertheless, the precise mechanism of action needs to be further elucidated.</p>
      <p>We conclude that imatinib acts as a dose-dependent inducer of cutaneous adverse reactions with mainly mild reactivity to low or intermediate doses (200&#x2013;600&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>) but severe eruptions to high doses (600&#x2013;1000&#x2009;mg&#x2009;day<sup>&#x2212;1</sup>) of the drug. Our findings should stimulate further investigation of the cutaneous reaction profile to imatinib. To avoid strong cutaneous adverse reactions, however, treatment with low or intermediate doses of imatinib should be preferred in comparison with high doses of this drug whenever feasible.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="bib1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Brouard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saurat</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous reactions to STI571</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>345</volume>
          <fpage>618</fpage>
          <lpage>619</lpage>
          <!--PubMed citation query: 'N Engl J Med||345|618||bib1|'-->
          <pub-id pub-id-type="pmid">11529225</pub-id>
        </citation>
      </ref>
      <ref id="bib2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Demetri</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>von Mehren</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Blanke</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>van den Abbeele</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Eisenberg</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Heinrich</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Tuveson</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Janicek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Silverman</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Silberman</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kiese</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Druker</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Corless</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Joensuu</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <fpage>472</fpage>
          <lpage>480</lpage>
          <!--PubMed citation query: 'N Engl J Med||347|472||bib2|'-->
          <pub-id pub-id-type="pmid">12181401</pub-id>
        </citation>
      </ref>
      <ref id="bib3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Druker</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Talpaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Resta</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Peng</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Buchdunger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ford</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Lydon</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Kantarjian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ohno-Jones</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sawyers</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Efficacy and safety of a specific inhibitor of the BCR&#x2013;ABL tyrosine kinase in chronic myeloid leukemia</article-title>
          <source>N Engl J Med</source>
          <year>2001</year>
          <volume>344</volume>
          <fpage>1031</fpage>
          <lpage>1037</lpage>
          <!--PubMed citation query: 'N Engl J Med||344|1031||bib3|'-->
          <pub-id pub-id-type="pmid">11287972</pub-id>
        </citation>
      </ref>
      <ref id="bib4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kantarjian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Sawyers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Guilhot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schiffer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Niederwieser</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Resta</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zoellner</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Talpaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Druker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ottmann</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Cony-Makhoul</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Facon</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tallman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schuster</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Loughran</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gratwohl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mandelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Saglio</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Lazzarino</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Baccarani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Morra</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>346</volume>
          <fpage>645</fpage>
          <lpage>652</lpage>
          <!--PubMed citation query: 'N Engl J Med||346|645||bib4|'-->
          <pub-id pub-id-type="pmid">11870241</pub-id>
        </citation>
      </ref>
      <ref id="bib5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Metcalfe</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Akin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Butterfield</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>McMahon</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Longley</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>1741</fpage>
          <lpage>1744</lpage>
          <!--PubMed citation query: 'Blood||99|1741||bib5|'-->
          <pub-id pub-id-type="pmid">11861291</pub-id>
        </citation>
      </ref>
      <ref id="bib6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ohashi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Funasaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ueda</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ichihashi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>c-KIT receptor expression in cutaneous malignant melanoma and benign melanotic naevi</article-title>
          <source>Melanoma Res</source>
          <year>1996</year>
          <volume>6</volume>
          <fpage>25</fpage>
          <lpage>30</lpage>
          <!--PubMed citation query: 'Melanoma Res||6|25||bib6|'-->
          <pub-id pub-id-type="pmid">8640066</pub-id>
        </citation>
      </ref>
      <ref id="bib7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sawyers</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Ottmann</surname>
              <given-names>OG</given-names>
            </name>
            <name>
              <surname>Schiffer</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Talpaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Guilhot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Deininger</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>O'Brien</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Reiffers</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Shea</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Chapuis</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Coutre</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Morra</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Saven</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Peschel</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gratwohl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mandelli</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ben-Am</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gathmann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Paquette</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Druker</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>3530</fpage>
          <lpage>3539</lpage>
          <!--PubMed citation query: 'Blood||99|3530||bib7|'-->
          <pub-id pub-id-type="pmid">11986204</pub-id>
        </citation>
      </ref>
      <ref id="bib8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talpaz</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silver</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Druker</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Goldman</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Gambacorti-Passerini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Guilhot</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schiffer</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Fischer</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Deininger</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Lennard</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Hochhaus</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ottmann</surname>
              <given-names>OG</given-names>
            </name>
            <name>
              <surname>Gratwohl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baccarani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tura</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Mahon</surname>
              <given-names>FX</given-names>
            </name>
            <name>
              <surname>Fernandes-Reese</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gathmann</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Capdeville</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kantarjian</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Sawyers</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
          <article-title>Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study</article-title>
          <source>Blood</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>1928</fpage>
          <lpage>1937</lpage>
          <!--PubMed citation query: 'Blood||99|1928||bib8|'-->
          <pub-id pub-id-type="pmid">11877262</pub-id>
        </citation>
      </ref>
      <ref id="bib9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>van Oosterom</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Judson</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Verweij</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stroobants</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Donato di Paola</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Dimitrijevic</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Martens</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sciot</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Van Glabbeke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Silberman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nielsen</surname>
              <given-names>OS</given-names>
            </name>
          </person-group>
          <article-title>Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study</article-title>
          <source>Lancet</source>
          <year>2001</year>
          <volume>358</volume>
          <fpage>1421</fpage>
          <lpage>1423</lpage>
          <!--PubMed citation query: 'Lancet||358|1421||bib9|'-->
          <pub-id pub-id-type="pmid">11705489</pub-id>
        </citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
